Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?

Moderna shares have surged more than 600% this year to around $225, following positive phase 3 results for its personalized melanoma vaccine with Merck's Keytruda; the stock has also joined the Nasdaq-100. The article cites cost reductions, newly approved vaccines and a broader oncology and rare-disease pipeline as growth drivers, but notes the share price is well above Wall Street's average 12-month estimate of $122 and advises watching for a potential dip.

Analysis

The key issue is not whether Moderna has a broader pipeline, but whether a promising combination-trial result can become a regulatorily accepted, commercially meaningful product before the post-pandemic revenue base erodes further. A filing is a milestone, not approval; verify the full trial data, regulator feedback, label scope, and the economics of the Merck collaboration before underwriting durable earnings. For Merck, a successful combination could support Keytruda’s franchise, but the article provides no basis to quantify incremental revenue or the partners’ split.

Near term, the Nasdaq-100 addition may support mechanical demand, but that flow is unlikely to validate the valuation after a sharp rerating. Over 1–3 months, the catalyst path is filing clarity and detailed efficacy/safety data; any delay, narrower-than-expected label, or safety concern could unwind event-driven buying. Over 6–18 months, the test is whether oncology and other launches produce measurable revenue while costs remain aligned with the smaller respiratory opportunity. Pipeline breadth alone does not establish a replacement for the former COVID-19 cash engine.

The contrarian risk is that investors extrapolate a single trial win into a successful commercial franchise. Conversely, a successful filing and approval could make the market’s old “COVID-only” framing too pessimistic. There is no supported basis here to infer fair value from the cited analyst estimate or to treat AI stocks as direct funding losers.

Key Decisions for Investors

• Do not chase a parabolic MRNA move solely on the trial headline or index inclusion. For new exposure, stage entry after the initial catalyst-driven repricing and confirm a regulatory submission and full trial details.
• For existing MRNA holders, consider trimming to a position size that can tolerate clinical and regulatory event risk; reassess on filing timing, label expectations, and subsequent revenue guidance rather than pipeline announcements alone.
• Set a thesis-failure watch: a filing delay, regulator concern, materially weaker full-data safety/efficacy profile, or guidance showing costs outpacing the post-COVID revenue base would argue against the bull case. A submission and eventual approval with credible commercial uptake would strengthen it.
• Track Merck separately: any MRNA oncology success may help Keytruda’s combination strategy, but do not trade MRK on assumed economics until collaboration terms and the incremental commercial opportunity are clearer.